Effects of Regular and Long-acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial

Manuscript Number: 

16-1256R2

Author(s): 
Laura D. Baker, Erin Caulder, Brenna A. Cholerton, Amy Claxton, Suzanne Craft, Deborah Dahl, Seth Friedman, Angela Hanson, Youngkyoo Jung, Joseph Maldjian, Thomas J. Montine, Bryan Neth, Emily H. Trittschuh, Christopher Whitlow

Disclosures

Laura D. Baker

  • Nothing to Disclose

Erin Caulder

  • Nothing to Disclose

Brenna A. Cholerton

  • Nothing to Disclose

Amy Claxton

  • Nothing to Disclose

Suzanne Craft

  • Lecture Fees:
    Received honorarium from speaking at AAIC2016 for Accera, inc.
    Grants
    • Agency: 
      Eli Lilly provides placebo and open label insulin for our ongoing clinical trial RF1AG041845
      Dates: 
      2012-present

Deborah Dahl

  • Nothing to Disclose

Seth Friedman

  • Nothing to Disclose

Angela Hanson

  • Nothing to Disclose

Youngkyoo Jung

  • Nothing to Disclose

Joseph Maldjian

  • Consulting Fees:
    BioClinica clinical trial consultation (unrelated to subject matter or materials discussed in the manuscript)

Thomas J. Montine

  • Nothing to Disclose

Bryan Neth

  • Nothing to Disclose

Emily H. Trittschuh

  • Nothing to Disclose

Christopher Whitlow

  • Nothing to Disclose